文献速递胸部肿瘤放疗放疗物理与技术

胸部再程放疗的疗效与安全性:基于累积EQD2剂量的分析

Re-irradiation in the thorax - An analysis of efficacy and safety based on accumulated EQD2 doses.
PubMed 文献 · Radiother Oncol · 2020-07-24

该单中心回顾性分析纳入2011年12月至2017年1月接受多次胸部放疗的42例连续患者,计算累积EQD2剂量分布并分析危及器官与靶区剂量参数。结果显示再程放疗后中位总生存19个月,12个月局部控制率52.6%,80%患者出现G1-G2毒性,即使部分危及器官累积最大剂量超过100 Gy3,毒性仍可接受。

要点

  • 胸部再程放疗后12个月局部控制率为52.6%,中位总生存为19个月。
  • 80%患者出现G1-G2毒性,最常见为咳嗽,仅1例G5并发症可能与再程放疗无关。
  • 部分危及器官累积最大D0.1cc超过100 Gy3,但总体毒性谱可接受。

核心结论

  • 即使多个危及器官接受累积最大剂量超过100 Gy3,胸部再程放疗的毒性仍可接受,局部控制与总生存令人鼓舞。

研究设计与样本

  • 单中心回顾性分析纳入2011年12月至2017年1月接受多次胸部放疗的42例连续患者,计算累积EQD2剂量分布并分析危及器官和靶区剂量参数。

主要发现

  • 所有放疗疗程的中位处方剂量为42.2 Gy(范围10-70.6 Gy)。
  • 双肺中位Dmean为10.1 Gy3(范围1.9-17.9 Gy3),最大D0.1cc为253.86 Gy3。
  • 食管中位D0.1cc为62.2 Gy3,最大103.78 Gy3;支气管树最大D0.1cc为187.33 Gy3(中位74.35 Gy3);主动脉最大D0.1cc为216.1 Gy3(中位70.9 Gy3)。
  • 首次再程放疗后中位总生存为19个月(范围1-45个月),再程放疗疗程后12个月局部控制率为52.6%。
  • 80%患者出现G1-G2毒性,最常见为咳嗽;1例患者出现G5并发症,可能与再程放疗无关。

临床怎么用

  • 胸部再程放疗规划时应计算累积EQD2剂量以评估危及器官受量,本研究中部分危及器官累积最大剂量超过100 Gy3仍观察到可接受毒性。

局限性

  • 本研究的局限性未在原文摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Thoracic re-irradiation remains a challenge regarding the balance of local efficacy and acceptable toxicities. In this retrospective analysis we analyzed dosimetrical and clinical data of patients treated with thoracic re-irradiation based on accumulated EQD2Gy doses. METHODS AND MATERIAL: We retrospectively analyzed the data of 42 consecutive single-institutional patients treated with repeated courses of thoracic radiotherapy from 12/2011 to 01/2017. Accumulated EQD2 dose distributions were calculated and dose parameters for organs at risk and target volumes were analysed. RESULTS: The median prescription dose was 42.2 Gy (10-70.6 Gy) for all RT courses. The median Dmean of both lungs was 10.1 Gy3 (range: 1.9 Gy3-17.9 Gy3) with a maximum D0.1 cc of 253.86 Gy3. The median D0.1 cc of the esophagus was 62.2 Gy3 with a maximum of 103.78 Gy3. The maximum D0.1 cc for the bronchial tree was 187.33 Gy3 (median 74.35 Gy3) and for the Aorta 216.1 Gy3 (median 70.9 Gy3). Median OS after first re-irradiation was 19 months (range 1-45 months). 12-month local control after a course of re-irradiation was 52.6%. 80% of patients suffered from a G1-G2 toxicity, most frequently coughing. One patient suffered from a G5 complication probably unrelated to re-irradiation. CONCLUSION: Even though several organs at risk received maximum accumulated doses of >100 Gy3, thoracic reirradiation resulted in an acceptable toxicity profile. Local tumor control and overall survival remained encouraging even after multiple courses of thoracic radiotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Schröder C, Stiefel I, Tanadini-Lang S, et al. Re-irradiation in the thorax - An analysis of efficacy and safety based on accumulated EQD2 doses. Radiother Oncol. 2020. PMID: 32717358. doi:10.1016/j.radonc.2020.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。